Type your tag names separated by a space and hit enter

Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options.

Abstract

Ulcerative colitis (UC), a subcategory of inflammatory bowel disease, afflicts 1-2 million people in the United States, and many more worldwide. Although the exact cause of ulcerative colitis remains undetermined, the condition appears to be related to a combination of genetic and environmental factors. While conventional treatments can be effective in maintaining remission and decreasing the length of active disease periods, the treatments are not without side effects, and a significant number of people suffering from UC fail to respond to even the strongest drugs. This article reviews potential unconventional treatments - transdermal nicotine, heparin, melatonin, DHEA, probiotics, fiber, dietary changes, botanicals, essential fatty acids, and other nutrients - that may be considered in conjunction with conventional approaches or as part of a comprehensive alternative treatment protocol. In addition this review addresses risk factors, pathogenesis, nutrient deficiencies, conventional treatment approaches, and extra-intestinal manifestations of the disease.

Links

  • FREE Publisher Full Text
  • Authors

    ,

    Source

    MeSH

    Butyric Acid
    Colitis, Ulcerative
    Diet
    Elements
    Fatty Acids
    Humans
    Nicotine
    Nicotinic Agonists
    Oxidative Stress
    Probiotics
    Smoking
    Sulfur
    Vitamins

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    12946238

    Citation

    Head, Kathleen A., and Julie S. Jurenka. "Inflammatory Bowel Disease Part 1: Ulcerative Colitis--pathophysiology and Conventional and Alternative Treatment Options." Alternative Medicine Review : a Journal of Clinical Therapeutic, vol. 8, no. 3, 2003, pp. 247-83.
    Head KA, Jurenka JS. Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options. Altern Med Rev. 2003;8(3):247-83.
    Head, K. A., & Jurenka, J. S. (2003). Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options. Alternative Medicine Review : a Journal of Clinical Therapeutic, 8(3), pp. 247-83.
    Head KA, Jurenka JS. Inflammatory Bowel Disease Part 1: Ulcerative Colitis--pathophysiology and Conventional and Alternative Treatment Options. Altern Med Rev. 2003;8(3):247-83. PubMed PMID: 12946238.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options. AU - Head,Kathleen A, AU - Jurenka,Julie S, PY - 2003/8/30/pubmed PY - 2003/12/12/medline PY - 2003/8/30/entrez SP - 247 EP - 83 JF - Alternative medicine review : a journal of clinical therapeutic JO - Altern Med Rev VL - 8 IS - 3 N2 - Ulcerative colitis (UC), a subcategory of inflammatory bowel disease, afflicts 1-2 million people in the United States, and many more worldwide. Although the exact cause of ulcerative colitis remains undetermined, the condition appears to be related to a combination of genetic and environmental factors. While conventional treatments can be effective in maintaining remission and decreasing the length of active disease periods, the treatments are not without side effects, and a significant number of people suffering from UC fail to respond to even the strongest drugs. This article reviews potential unconventional treatments - transdermal nicotine, heparin, melatonin, DHEA, probiotics, fiber, dietary changes, botanicals, essential fatty acids, and other nutrients - that may be considered in conjunction with conventional approaches or as part of a comprehensive alternative treatment protocol. In addition this review addresses risk factors, pathogenesis, nutrient deficiencies, conventional treatment approaches, and extra-intestinal manifestations of the disease. SN - 1089-5159 UR - https://www.unboundmedicine.com/medline/citation/12946238/full_citation L2 - http://archive.foundationalmedicinereview.com/publications/8/3/247.pdf DB - PRIME DP - Unbound Medicine ER -